VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
FATE
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
FATEFate Therapeutics, Inc.
$1.14$133M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksFATEBalance Sheet

Fate Therapeutics, Inc. (FATE) Balance Sheet

15Y historyFree accessUpdated daily

Total assets have halved 54% to $260.1M and equity has fallen 64% to $153.4M even as total debt only declined modestly to $75.7M, driving the D/E ratio from 0.24 to 0.49 and leaving cash of $32.4M covering only a few months of operations.

Income StatementBalance SheetCash FlowRatios

FATE Balance Sheet

Annual statement

FATE Balance Sheet

Fate Therapeutics, Inc. (FATE) balance sheet — 15-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Total Current Assets144.26M208.7M291.91M331.54M502.07M633.41M494.32M227.09M205.2M102.6M93.32M65.65M49.87M54.65M9.79M6.69M
Cash & Short-Term Investments139.13M203.66M279.07M315.18M436.23M615.91M482.92M221.43M201.01M100.95M92.11M64.81M49.1M54.04M9.09M6.39M
Cash Only43.94M46.63M36.06M41.87M61.33M133.58M167.35M99.81M190.51M88.95M88.61M64.81M49.1M54.04M9.09M6.39M
Short-Term Investments95.19M157.03M243.01M273.31M374.89M482.33M315.57M121.61M10.49M12M3.5M00000
Accounts Receivable479K916K3.54M1.83M38.48M8.68M5.51M0500K0000000
Days Sales Outstanding53.8350.3194.7610.49145.8556.764.04-38.5-------
Inventory0000000000000000
Days Inventory Outstanding----------------
Other Current Assets04.13M9.3M900K27.37M1.1M5.89M5.66M01.65M1.21M843K771K615K00
Total Non-Current Assets94.02M110.23M148.78M174.68M203.49M288.04M128.13M75.19M7.84M2.7M1.73M2.31M1.33M932K1.28M1.16M
Property, Plant & Equipment88.92M98.53M110.89M158.51M66.07M162.25M99.39M22.75M5.13M2.55M1.58M2.16M1.2M810K1.16M1.04M
Fixed Asset Turnover0.05x0.07x0.12x0.40x1.46x0.34x0.32x0.47x0.92x1.61x2.79x1.13x-1.20x2.30x1.12x
Goodwill0000000000000000
Intangible Assets0000000000000000
Long-Term Investments1.47M1.47M27.66M980K4.94M100.66M28.73M39.44M2.19M122K122K122K0000
Other Non-Current Assets5.1M10.23M10.24M15.19M132.48M25.13M9K12.99M526K24K24K24K132K122K122K122K
Total Assets238.28M318.94M440.69M506.22M705.56M921.46M622.46M302.27M213.03M105.29M95.05M67.96M51.2M55.58M11.08M7.85M
Asset Turnover0.02x0.02x0.03x0.13x0.14x0.06x0.05x0.04x0.02x0.04x0.05x0.04x-0.02x0.24x0.15x
Asset Growth %-116.84%-27.63%-12.94%-28.25%-23.43%48.04%105.92%41.89%102.33%10.78%39.86%32.72%-7.88%401.83%41.06%-
Total Current Liabilities32.69M36.07M38.52M39.09M114.05M81.28M85.56M27.81M27.26M11.05M15.19M13.44M4.58M4.6M4.85M3.67M
Accounts Payable2.92M2.66M9.37M4.72M8.27M8.61M6.28M5.82M4.21M1.68M934K996K645K682K1.23M1.86M
Days Payables Outstanding197.5775.1428.8410.96219.27537.3318.26-27.417.8312.8918.314.3220.7337.35-
Short-Term Debt0006.18M003.35M02.44M08.19M7.55M1.55M1.73M1.94M1.25M
Deferred Revenue (Current)963K381K393K685K42.23M21.48M21.14M2.79M7.59M2.1M2.1M2.4M2.26M2.09M63K146K
Other Current Liabilities9.51M8.45M11.64M16.95M40.03M3.2M49.97M12.18M10.09M5.5M2.46M1.5M130K147K327K221K
Current Ratio4.41x5.79x7.58x8.48x4.40x7.79x5.78x8.17x7.53x9.29x6.14x4.88x10.89x11.88x2.02x1.82x
Quick Ratio4.41x5.79x7.58x8.48x4.40x7.79x5.78x8.17x7.53x9.29x6.14x4.88x10.89x11.88x2.02x1.82x
Cash Conversion Cycle-143.74---------------
Total Non-Current Liabilities72.55M75.68M83.45M98.71M107.57M161.33M152.45M29.71M25.3M17.05M6.71M16.48M18.28M135K59.05M54.86M
Long-Term Debt073.29M00000012.45M14.81M2.5M10.69M18.08M01.73M3.59M
Capital Lease Obligations140.14M077.85M97.36M103.71M109.24M93.94M25.23M00000000
Deferred Tax Liabilities0000000000000000
Other Non-Current Liabilities3.17M2.4M5.6M1.35M3.86M24.97M12.48M702K5.35M1.52M1.38M857K200K135K57.32M51.27M
Total Liabilities105.24M111.75M121.97M137.8M221.62M242.62M238.01M57.52M52.56M28.1M21.89M29.92M22.86M4.74M63.9M58.53M
Total Debt74.49M77.85M85.27M103.54M109.34M114.82M97.3M26.93M14.88M14.81M10.69M18.24M19.63M1.73M3.67M4.84M
Net Debt30.55M31.22M49.21M61.67M48.01M-18.77M-70.05M-72.89M-175.63M-74.14M-77.92M-46.57M-29.47M-52.3M-5.41M-1.55M
Debt / Equity0.56x0.38x0.27x0.28x0.23x0.17x0.25x0.11x0.09x0.19x0.15x0.48x0.69x0.03x--
Debt / EBITDA-0.62x---------------
Net Debt / EBITDA-0.26x---------------
Interest Coverage--------55.02x-38.27x-32.87x-19.44x-12.51x-46.15x-25.25x-28.24x-104.72x
Total Equity133.03M207.18M318.73M368.42M483.94M678.84M384.44M244.76M160.47M77.19M73.15M38.04M28.34M50.85M-52.83M-50.68M
Equity Growth %-157.14%-35%-13.49%-23.87%-28.71%76.58%57.07%52.53%107.89%5.52%92.32%34.22%-44.27%196.26%-4.23%-
Book Value per Share1.081.742.803.745.007.164.673.592.861.842.301.491.392.57-5.96-5.72
Total Shareholders' Equity133.03M207.18M318.73M368.42M483.94M678.84M384.44M244.76M160.47M77.19M73.15M38.04M28.34M50.85M-52.83M-50.68M
Common Stock122K115K114K99K97K96K88K76K65K53K41K29K21K20K1K1K
Retained Earnings-1.63B-1.53B-1.4B-1.21B-1.05B-769.08M-556.93M-383.55M-285.4M-218.8M-175.85M-142.38M-112.39M-86.51M-65.61M-51.38M
Treasury Stock0000000000000000
Accumulated OCI-155K116K268K15K-1.85M-762K70K22K-2K-3K-1K-3.47M-2.79M-2.3M-1.75M-1.16M
Minority Interest0000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

Cash depletion outpacing financing options

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Asset Base Halves Over Ten Quarters

FATE's total assets have contracted 54%, from $569.9M in 2024Q1 to $260.1M in 2026Q2, while equity fell 64% to $153.4M, per the company's quarterly balance sheets, a trajectory driven by sustained operating losses consuming the balance sheet rather than by divestitures.

The roughly $31M average quarterly decline in total assets tracks closely with the operating losses documented in FATE's income statements, implying the company is funding its burn by liquidating balance-sheet resources rather than through external capital raises. Importantly, this erosion shows no sign of decelerating: the last four quarters removed about $185M of assets, a pace that, if sustained, would exhaust the remaining $260M asset base well before any commercial inflection. For a pre-revenue biotech, this pattern signals deteriorating business quality trajectory rather than temporary working-capital volatility.

Stable Borrowings Mask Equity-Driven Leverage Drift

Total debt has declined modestly from $102.1M to $75.7M over ten quarters, yet FATE's debt-to-equity ratio has doubled from 0.24 to 0.49, based on FATE's reported figures, because the equity denominator is shrinking far faster than obligations are being retired.

The near-flat debt trajectory suggests FATE is servicing but not aggressively pre-paying its obligations, meaning the leverage drift is a symptom of balance-sheet erosion rather than new borrowing — a distinction that matters for assessing whether the capital structure is strategically leveraged or deteriorating by default. At 0.49, FATE now carries materially higher relative leverage than CRSP (0.21), NTLA (0.14), and BEAM (0.24), though its absolute debt quantum remains modest. Investors should monitor whether the company draws further on debt facilities to bridge its cash shortfall, which would compound an already worsening leverage profile.

Cash Reserves Fall to Emergency Territory

Cash declined from $121.3M in 2024Q1 to $32.4M in 2026Q2, per FATE's balance sheets, and against roughly $23.5M of quarterly free cash outflow reported for 2026Q2, the unencumbered cash balance appears to cover only a few months of operations absent new financing.

The current ratio of 4.85 in 2026Q2, though down sharply from 8.69 two years prior, appears difficult to reconcile with the $260.1M total asset base and $32.4M cash line, so the true composition of FATE's current assets warrants verification before relying on the ratio as a liquidity buffer. What is unambiguous is the direction: cash has fallen for nine consecutive quarters, and the modest sequential upticks (e.g., $39.6M to $32.4M reversal in Q2) suggest no replenishment event occurred during the period. Compared with peers holding $146M–$355M in cash, FATE's liquidity position appears the most exposed to a near-term financing or restructuring decision.

Shrinking PPE Confirms Outsourced Manufacturing Model

Net property, plant, and equipment has fallen 40%, from $152.7M in 2024Q1 to $92.1M in 2026Q2, while goodwill remained at zero across all ten quarters, per FATE's filings, indicating depreciation is consuming the asset base faster than replacement investment occurs.

Consistent with the cash flow finding that cumulative capex of ~$8.2M is dwarfed by ~$36.7M of cumulative depreciation, the PPE decline implies FATE's legacy manufacturing infrastructure is being run down rather than maintained, reinforcing an increasingly asset-light, outsourced production footprint. This carries a dual read: the absence of goodwill eliminates impairment risk entirely, a genuine relative strength, but the depreciating PPE base suggests limited in-house production capacity remains available to support any future commercial scale-up without incremental capital. The $92.1M residual book value may therefore overstate the productive capacity currently embedded in FATE's operations.

Book Equity Erodes Despite SBC Cushion

Shareholders' equity declined from $426.1M to $153.4M over ten quarters while accumulated deficits deepened to -$1.6B, per FATE's balance sheets, with cumulative net losses exceeding equity erosion — a gap suggesting stock-based compensation partially offset, but did not prevent, the deterioration in book value.

The ~$273M equity decline is smaller than the ~$384M of cumulative net losses cited in FATE's income statements, implying roughly $74M of stock-based compensation and other non-cash items propped up book equity during the period. However, as SBC has contracted 68% to $3.5M per quarter, this cushion is disappearing, meaning future equity erosion should track cash losses more directly. With no buybacks or dividends deployed across the decade's quarters, the equity contraction is entirely loss-driven — an unambiguous signal that the remaining $153.4M book value is being consumed to fund ongoing operations rather than preserved for strategic optionality.

Deferred Revenue Vacuum Removes Forward Cover

Deferred revenue fell to zero in 2026Q2 from $600K in 2024Q3, per FATE's reported filings, eliminating even the modest contracted-backlog signal that previously implied near-term collaboration infusions and leaving the balance sheet with essentially no forward revenue visibility.

The non-obvious risk here is the interaction between a zero-deferred-revenue position and FATE's milestone-dependent revenue model: without any contracted liabilities representing pre-paid partner obligations, there is no balance-sheet evidence of committed future collaboration cash, making the remaining $32.4M cash position the sole measurable buffer. This contrasts with the income statement's occasional 100% gross-margin quarters, which create an illusion of commercial viability that the balance sheet does not corroborate. Combined with the doubled D/E ratio and nine consecutive quarters of cash decline, the balance sheet suggests FATE's headline solvency metrics understate the immediacy of its financing need.

FATE — Frequently Asked Questions

Quick answers to the most common questions about buying FATE stock.

What are the total assets of Fate Therapeutics, Inc. (FATE)?

As of 2025, Fate Therapeutics, Inc. (FATE) had total assets of $318.9M including $208.7M in current assets.

How much debt does Fate Therapeutics, Inc. (FATE) have?

Fate Therapeutics, Inc. (FATE) carries total debt of $77.8M, offset by $203.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Fate Therapeutics, Inc.?

Fate Therapeutics, Inc. (FATE) has total shareholders' equity (book value) of $207.2M ($1.74 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Fate Therapeutics, Inc.'s current ratio and liquidity?

Fate Therapeutics, Inc. (FATE) reported a current ratio of 5.79x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.